公开(公告)号：US20140031433A1

公开(公告)日：2014-01-30

申请号：US13738827

申请日：2013-01-10

Applicant: EDISON PHARMACEUTICALS, INC.

Inventor： Guy M. MILLER ,  William D. SHRADER ,  Viktoria KHEIFETS

IPC: A61K31/122

CPC classification number: A61K31/122 ,  A61K9/0048 ,  A61K9/0053 ,  A61K31/353 ,  A61K47/44

Abstract: A formulation, comprising an ophthalmically effective amount of one or more tocotrienol quinones, particularly of alpha-tocotrienol quinone is disclosed. Use of a formulation comprising one or more tocotrienol quinones for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more tocotrienol quinones is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more tocotrienol quinones is also discussed.

Abstract translation: 公开了包含眼睛有效量的一种或多种生育三烯酚醌，特别是α-生育三烯酚醌的制剂。 还讨论了包含一种或多种生育三烯酚醌的制剂用于预防，减少，改善或治疗与神经退行性或创伤性病症相关的眼科疾病的用途。 还讨论了用包含一种或多种生育三烯酚醌的制剂治疗或控制与神经变性疾病或创伤相关的眼部症状的方法。 还讨论了用包含一种或多种生育三烯酚醌的制剂治疗或控制与线粒体肌病相关的眼部症状的方法。

公开(公告)号：US20130289034A1

公开(公告)日：2013-10-31

申请号：US13924363

申请日：2013-06-21

Applicant: Edison Pharmaceuticals, Inc.

Inventor： Orion D. JANKOWSKI ,  Kieron E. WESSON ,  Paul MOLLARD ,  William D. SHRADER

IPC: C07C235/78 ,  C07D295/192 ,  C07D311/66 ,  C07D213/40 ,  C07D207/27 ,  C07D265/30 ,  C07D211/46 ,  C07D295/13

CPC classification number: C07C235/80 ,  C07C235/78 ,  C07C317/28 ,  C07C2601/02 ,  C07C2601/16 ,  C07D207/26 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D213/50 ,  C07D233/61 ,  C07D265/30 ,  C07D295/116 ,  C07D295/13 ,  C07D295/185 ,  C07D295/192 ,  C07D311/66

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US20160039776A1

公开(公告)日：2016-02-11

申请号：US14776688

申请日：2014-03-14

Applicant: EDISON PHARMACEUTICALS, INC.

Inventor： Andrew W. HINMAN ,  Dana DAVIS ,  William D. SHRADER

IPC: C07D279/20

CPC classification number: C07D279/20 ,  C07D241/46 ,  C07D279/18

Abstract: Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

Abstract translation: 本文公开了吩嗪-3-酮和吩噻嗪-3-酮衍生物化合物以及使用这些化合物治疗或抑制氧化应激障碍（包括线粒体病症，受损能量加工障碍，神经变性疾病和衰老疾病）的方法。

公开(公告)号：US20160115141A1

公开(公告)日：2016-04-28

申请号：US14894277

申请日：2014-05-30

Applicant: EDISON PHARMACEUTICALS, INC.

Inventor： Andrew W. HINMAN ,  Viktoria KHEIFETS ,  William D. SHRADER

IPC: C07D307/33 ,  C07C235/78 ,  C07C69/732

CPC classification number: C07D307/33 ,  C07C66/00 ,  C07C69/732 ,  C07C69/95 ,  C07C235/78 ,  C07C2601/02 ,  C07C2601/10 ,  C07C2601/16

Abstract: Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are quinone or naphthoquinone compounds with carboxylic acid or carboxylic acid derivative substituents.

Abstract translation: 本文公开了使用这些化合物治疗或抑制氧化应激障碍（包括线粒体病症，受损能量加工障碍，神经退行性疾病和衰老疾病）或用于调节一种或多种能量生物标志物，使一种或多种能量生物标志物归一化的化合物和方法， 或增强一种或多种能量生物标志物，其中所述化合物是具有羧酸或羧酸衍生物取代基的醌或萘醌化合物。

公开(公告)号：US20160075638A1

公开(公告)日：2016-03-17

申请号：US14829534

申请日：2015-08-18

Applicant: Edison Pharmaceuticals, Inc.

Inventor： Orion D. JANKOWSKI ,  Kieron E. WESSON ,  Paul MOLLARD ,  William D. SHRADER

IPC: C07C235/80 ,  C07D295/116 ,  C07D265/30 ,  C07D213/50 ,  C07D207/26 ,  C07D211/46 ,  C07D233/61

CPC classification number: C07C235/80 ,  C07C235/78 ,  C07C317/28 ,  C07C2601/02 ,  C07C2601/16 ,  C07D207/26 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D213/50 ,  C07D233/61 ,  C07D265/30 ,  C07D295/116 ,  C07D295/13 ,  C07D295/185 ,  C07D295/192 ,  C07D311/66

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US20160039775A1

公开(公告)日：2016-02-11

申请号：US14776683

申请日：2014-03-14

Applicant: EDISON PHARMACEUTICALS, INC.

Inventor： Andrew W. HINMAN ,  Dana DAVIS ,  William D. SHRADER

IPC: C07D265/38 ,  C07H17/00

CPC classification number: C07D265/38 ,  C07D413/10 ,  C07H17/00

Abstract: Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

Abstract translation: 本文公开了雷公藤衍生物化合物和使用这些化合物治疗或抑制氧化应激障碍（包括线粒体病症，受损能量加工障碍，神经变性疾病和衰老疾病）的方法。